What is one challenge that arises from using radiolabeled antibodies in therapies?

Using radiolabeled antibodies in therapies presents several challenges, one of which is ensuring effectiveness and stability. Radiolabeled antibodies must maintain their structural integrity and biological activity after being labeled with a radioactive isotope. If the labeling process alters the antibody's ability to bind to the target antigen effectively, this can significantly reduce the therapeutic efficacy. Additionally, the stability of the radioactive label is crucial; if the label degrades or dissociates from the antibody during storage or within the body, the treatment may not deliver the intended therapeutic dose to the target tissue. Therefore, ensuring both the effectiveness of the antibody in binding and the stability of the radiolabel is a significant challenge in the development and application of radiolabeled antibody therapies.

The other options depict challenges that may not be the primary focus when using radiolabeled antibodies. For example, while antibodies do have shelf lives and side effects may occur, these issues aren't as central to the fundamental challenge of maintaining effectiveness and stability in the context of the therapy. Increasing the dosage is also not a direct challenge associated with using radiolabeled antibodies; rather, it might depend on the specific treatment protocol and the distribution of the drug within the body.